

## **Sunesis Pharmaceuticals Hosts Conference Call to Discuss Preliminary SNS-595 Activity in its Ovarian Cancer Clinical Trial Being Reported at the AACR-NCI-EORTC International Conference**

October 23, 2007 1:30 PM ET

SOUTH SAN FRANCISCO, Calif., Oct 23, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), today announced that management will host a conference call this afternoon at 3:30 p.m. Eastern Time/12:30 p.m. Pacific Time to review preliminary data from Sunesis' ongoing Phase 2 clinical trial of SNS-595 in platinum-resistant ovarian cancer. Joining management on the call will be a clinical investigator participating in the current clinical trial.

Preliminary data from the Phase 2 clinical trial are being presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Abstract #A158, a poster titled "A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer." The poster will be on view as part of Poster Session A -- Clinical Trials in the Moscone Convention Center West Exhibit Hall and will also be available on the Sunesis corporate website at <http://www.sunesis.com>.

Individual and institutional investors can access the call via (877) 681-3375 (U.S. and Canada) or (719) 325-4888 (international). To access the live audio webcast or the subsequent archived recording, visit the "Investors and Media -- Calendar of Events" section of the Sunesis website at <http://www.sunesis.com>. Please log on to Sunesis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.

### About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit <http://www.sunesis.com>.

SOURCE Sunesis Pharmaceuticals, Inc.

<http://www.sunesis.com>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX